Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-27
2007-03-27
Schultz, James (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
10380195
ABSTRACT:
Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.
REFERENCES:
patent: 5929040 (1999-07-01), Werther et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: WO 00/69454 (2000-11-01), None
Steller, et al. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc. Natl. Acad. Sci., Dec. 1995, vol. 92, pp. 11970-11974.
Corkins et al. Growth Stimulation By Transfection of Intestinal Epithelial Cells With An Antisense Insulin-Like Growth Factor Binding Protein-2 Construct. Biochem. Biophys. Res. Com. Jun. 26, 1995, vol. 211, No. 3, pp. 707-713.
Wang, et al. Correlation of Glioma Cell Regression with Inhibition of Insulin-Like Growth Factor Binding Protein-2 Expression. Neuroendocrinology. 1997, vol. 66, pp. 203-211.
Bubendorf, et al., “Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays”, Oct. 20, 1999, pp. 1758-1764, vol. 91, No. 20, Publisher: Journal of the National Cancer Institute; US Dept. of Health, Education and Welfare; Public Health, Published in: USA.
Forsyth, et al., “Growth Inhibition of a Human Colon Cancer Cell Line by Antisense Oligonucleotide to IGFBP-2”, 1995, p. A726, vol. 108, No. 4, Publisher: Gastroenterology, Saunders, Published in: Philadelphia, PA, USA.
Gleave, et al., “Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer”, 2003, pp. 209-221, vol. 4, No. 3, Publisher: Current Drug Targets; Bentham Science Publisher, Published in: USA.
Miyake, et al., “Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models”; Jun. 1, 2000, pp. 3058-3064, Publisher: Cancer Research, American Association for Cancer Research, Published in: Baltimore, MD, USA.
Binkert, et al., “Structure of the Human Insulin-Like Growth Factor Binding Protein-2 Gene”, 1992, pp. 826-836, vol. 6, No. 5, Publisher: Molecular Endocrinology, Published in: US.
Gleave Martin
Nelson Colleen
Rennie Paul S.
Satoshi Kiyama
Marina Larson & Associates LLC
Schultz James
The University of British Columbia
Vivlemore Tracy
LandOfFree
Antisense insulin-like growth factor binding protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense insulin-like growth factor binding protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense insulin-like growth factor binding protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3765092